Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 10:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,728 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Blood Cancer Clear all
Terminated Phase 2 Interventional Results available

2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis

NCT00075608
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Neoplasm
Interventions
filgrastim, melphalan, autologous stem cell transplantation, stem cell infusion
Biological · Drug · Procedure
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Jun 10, 2026, 10:23 PM EDT
Completed Phase 1 Interventional

Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer

NCT00104923
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
fenretinide
Drug
Lead sponsor
California Cancer Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
4
States / cities
Los Angeles, California • Bethesda, Maryland • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Jun 10, 2026, 10:23 PM EDT
Completed Phase 1 Interventional

Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies

NCT02543879
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma
Interventions
FT-1101, Azacitidine
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
8
States / cities
Los Angeles, California • Sarasota, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2023 · Synced Jun 10, 2026, 10:23 PM EDT
Completed Early Phase 1 Interventional

Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases

NCT00424242
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Metastatic Cancer, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Pemetrexed
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Jun 10, 2026, 10:23 PM EDT
Withdrawn Phase 2 Interventional

A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia

NCT00594555
View directory record Official record
Conditions
Chronic Myeloid Leukemia, Blast Crisis, Acute Myeloid Leukemia
Interventions
Imatinib Mesylate, CLAG
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2008 · Synced Jun 10, 2026, 10:23 PM EDT
Completed Phase 1 Interventional

High Dose Ascorbic Acid for Plasma Cell Disorders

NCT03602235
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ascorbate, Melphalan
Other · Drug
Lead sponsor
Christopher Strouse
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Jun 10, 2026, 10:23 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

NCT07008118
View directory record Official record
Conditions
Myeloproliferative Neoplasms
Interventions
INCA035784
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Phoenix, Arizona • Palo Alto, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jun 10, 2026, 10:23 PM EDT
Recruiting Phase 1 Interventional

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT06001788
View directory record Official record
Conditions
AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type
Interventions
Ziftomenib, Fludarabine, Idarubicin, Cytarabine, Gilteritinib, Granulocyte colony-stimulating factor
Drug · Biological
Lead sponsor
Kura Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
38
States / cities
Gilbert, Arizona • Los Angeles, California • Orange, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jun 10, 2026, 10:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

NCT01001442
View directory record Official record
Conditions
Multiple Myeloma
Interventions
BT062
Drug
Lead sponsor
Biotest Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Jun 10, 2026, 10:23 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Pentostatin and Targeted Busulfan

NCT00496340
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Pentostatin, Busulfan, Rituximab, Allogeneic Hematopoietic Cell Transplant
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Jun 10, 2026, 10:23 PM EDT
Completed Phase 2 Interventional Results available

Acupuncture for Chemo-Induced Peripheral Neuropathy

NCT00891618
View directory record Official record
Conditions
Lymphoma, Myeloma, Peripheral Neuropathy
Interventions
Acupuncture
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2016 · Synced Jun 10, 2026, 10:23 PM EDT
Completed Not applicable Interventional Results available

Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant

NCT01852591
View directory record Official record
Conditions
Multiple Myeloma
Interventions
PCV 13
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Jun 10, 2026, 10:23 PM EDT
Active, not recruiting Phase 2 Interventional Results available

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

NCT02180724
View directory record Official record
Conditions
Waldenström Macroglobulinemia (WM)
Interventions
Acalabrutinib (ACP-196)
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
10
States / cities
Santa Barbara, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jun 10, 2026, 10:23 PM EDT
Completed Phase 2 Interventional

Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS

NCT00001059
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Doxorubicin hydrochloride (liposomal), Filgrastim, Bleomycin sulfate, Vincristine sulfate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2012 · Synced Jun 10, 2026, 10:23 PM EDT
Completed Phase 3 Interventional

Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma

NCT00044759
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
Piperacillin/Tazobactam (Tazocin)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
31
States / cities
Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2007 · Synced Jun 10, 2026, 10:23 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

NCT01949662
View directory record Official record
Conditions
Advanced Cancers
Interventions
Lorazepam, Placebo, Haloperidol decanoate, Questionnaires
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jun 10, 2026, 10:23 PM EDT
Completed Phase 1 Interventional

Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

NCT03524235
View directory record Official record
Conditions
Multiple Myeloma, CLL, Chronic Lymphocytic Leukemia, Lymphoma, Hodgkin Lymphoma
Interventions
Total Body Irradiation, Haploidentical Stem Cell Transplantation, CD56-Enriched Donor Lymphocyte Infusion, Bendamustine, Fludarabine, Rituximab
Radiation · Procedure · Biological + 1 more
Lead sponsor
Noah Merin
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Jun 10, 2026, 10:23 PM EDT
Enrolling by invitation No phase listed Observational

Collection of Blood and Urine From Patients Undergoing Radiation Therapy

NCT00027326
View directory record Official record
Conditions
Carcinoma, Cancer, Tumor
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 10, 2026, 10:23 PM EDT
Completed No phase listed Observational

HIV Infection and Tobacco Use Among Injection Drug Users in Baltimore, Maryland: A Pilot Study of Biomarkers

NCT00491335
View directory record Official record
Conditions
HIV Infections, AIDS, Lung Cancer, Tobacco Addiction, Drug Addiction
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
17 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 10:23 PM EDT
Recruiting Phase 3 Interventional

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

NCT06208150
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Talquetamab, Pomalidomide, Teclistamab, Elotuzumab, Dexamethasone, Bortezomib
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
49
States / cities
Clovis, California • Santa Monica, California • New Haven, Connecticut + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 10, 2026, 10:23 PM EDT
Completed Phase 1 Interventional

Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors

NCT00003597
View directory record Official record
Conditions
Cancer
Interventions
recombinant human thrombopoietin, carboplatin, etoposide, ifosfamide, G-CSF
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
23
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Jun 10, 2026, 10:23 PM EDT
Not listed Phase 1 Interventional

Cardiac Safety Assessment Study of Picoplatin in Solid Tumors

NCT00710697
View directory record Official record
Conditions
Solid Tumors
Interventions
Picoplatin
Drug
Lead sponsor
Poniard Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2009 · Synced Jun 10, 2026, 10:23 PM EDT
Completed Early Phase 1 Interventional

Non Invasive Oral Cancer Screening Among HIV Infected Individuals

NCT02823847
View directory record Official record
Conditions
Malignant Neoplasms of Mesothelial and Soft Tissue, Human Immunodeficiency Virus
Interventions
Screening Interview, Carbon Monoxide Test, Self-Help Materials, Visual Oral Screening Examination, Direct Fluorescent Oral Visualization Examination, Oral Biopsy
Behavioral · Device · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2022 · Synced Jun 10, 2026, 10:23 PM EDT
Completed Phase 2 Interventional

Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00049374
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
oblimersen sodium, dexamethasone, thalidomide
Biological · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Jun 10, 2026, 10:23 PM EDT